ArticleVirus genes2025
IGFBP2 up-regulation by EBV via TGF-β signaling: a key mechanism in nasopharyngeal carcinoma progression.
Article in Virus genes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rewiring the tumor microenvironment: IGFBP2 at the Nexus of remodeling and therapy resistance?Biochimica et biophysica acta. Reviews on cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The key carcinogenic factor for nasopharyngeal cancer (NPC) is infection with the Epstein-Barr virus (EBV), significantly contributing to its occurrence and development. Insulin-like growth factor binding protein 2 (IGFBP2), known for its aberrant expression in various cancers, plays a pivotal role in oncogenic networks. Investigating IGFBP2's function and mechanism in EBV-associated NPC was the goal of the current study. The findings indicated that IGFBP2 expression was markedly higher in EBV-positive NPC cells compared to EBV-negative NPC cells, and EBV could up-regulate IGFBP2 expression by activating the TGF-β pathway through its encoded EBNA1. Furthermore, IGFBP2 influenced key carcinogenic processes, including proliferation, migration, epithelial-mesenchymal transition (EMT), and cell cycle progression in NPC cells. Notably, knockdown of IGFBP2 in the EBV-infected epithelial cell line C666-1 led to a reduction in the expression of EBV-encoded latent and lytic phase gene proteins, as well as a decrease in the copy number of the EBV genome. These results point to a reciprocal regulation link between EBV and IGFBP2, opening up a promising avenue for future clinical treatment and experimental research.
Indexed as
Identifiers
40665173What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.